Skip Nav Destination
Issues
1 January 2015
-
Cover Image
Cover Image
The cover shows the results of an unsupervised two-dimensional hierarchical clustering analysis of the 5,000 most variable genes classifying breast tumors into ER+, HER2+, or triple-negative (ER−, PR−, HER2−) subtypes. The analysis was performed on 800 breast tumors obtained from the Karolinska Institutet, Sweden. The RAS gene expression signature was high in the triple-negative subtype and low in the ER+ subtype. For details, see the article by Di Cosimo and colleagues on page 49 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR 20th Anniversary Commentary
CCR Translations
CCR New Strategies
Molecular Pathways
Cancer Therapy: Clinical
Author Choice
Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Joseph A. Califano; Zubair Khan; Kimberly A. Noonan; Lakshmi Rudraraju; Zhe Zhang; Hao Wang; Steven Goodman; Christine G. Gourin; Patrick K. Ha; Carole Fakhry; John Saunders; Marshall Levine; Mei Tang; Geoffrey Neuner; Jeremy D. Richmon; Ray Blanco; Nishant Agrawal; Wayne M. Koch; Shanthi Marur; Donald T. Weed; Paolo Serafini; Ivan Borrello
Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Donald T. Weed; Jennifer L. Vella; Isildinha M. Reis; Adriana C. De la fuente; Carmen Gomez; Zoukaa Sargi; Ronen Nazarian; Joseph Califano; Ivan Borrello; Paolo Serafini
Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Serena Di Cosimo; Sriram Sathyanarayanan; Johanna C. Bendell; Andrés Cervantes; Mark N. Stein; Irene Braña; Desamparados Roda; Brian B. Haines; Theresa Zhang; Christopher G. Winter; Sharda Jha; Youyuan Xu; Jason Frazier; Richard A. Klinghoffer; Ann Leighton-Swayze; Yang Song; Scot Ebbinghaus; José Baselga
Author Choice
A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
Wells A. Messersmith; Geoffrey I. Shapiro; James M. Cleary; Antonio Jimeno; Arvind Dasari; Bo Huang; M. Naveed Shaik; Rossano Cesari; Xianxian Zheng; Jennifer M. Reynolds; Patricia A. English; Karen R. McLachlan; Kenneth A. Kern; Patricia M. LoRusso
A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Kim A. Reiss; Joseph M. Herman; Marianna Zahurak; Anthony Brade; Laura A. Dawson; Angela Scardina; Caitlin Joffe; Emily Petito; Amy Hacker-Prietz; Robert J. Kinders; Lihua Wang; Alice Chen; Sarah Temkin; Naomi Horiba; Lillian L. Siu; Nilofer S. Azad
First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Debashis Sarker; Joo Ern Ang; Richard Baird; Rebecca Kristeleit; Krunal Shah; Victor Moreno; Paul A. Clarke; Florence I. Raynaud; Gallia Levy; Joseph A. Ware; Kathryn Mazina; Ray Lin; Jenny Wu; Jill Fredrickson; Jill M. Spoerke; Mark R. Lackner; Yibing Yan; Lori S. Friedman; Stan B. Kaye; Mika K. Derynck; Paul Workman; Johann S. de Bono
Personalized Medicine and Imaging
Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Antiangiogenic Treatment Effects in Multiple Myeloma
Maximilian Merz; Judith Ritsch; Christina Kunz; Barbara Wagner; Sandra Sauer; Dirk Hose; Thomas Moehler; Stefan Delorme; Hartmut Goldschmidt; Christian Zechmann; Jens Hillengass
Cancer Therapy: Preclinical
Author Choice
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Hirdesh Uppal; Estelle Doudement; Kaushiki Mahapatra; Walter C. Darbonne; Daniela Bumbaca; Ben-Quan Shen; Xiaoyan Du; Ola Saad; Kristin Bowles; Steve Olsen; Gail D. Lewis Phillips; Dylan Hartley; Mark X. Sliwkowski; Sandhya Girish; Donna Dambach; Vanitha Ramakrishnan
The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB
Changchun Deng; Mark Lipstein; Richard Rodriguez; Xavier O. Jirau Serrano; Christine McIntosh; Wei-Yann Tsai; Andrew S. Wasmuth; Susan Jaken; Owen A. O'Connor
CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin
Clara Guerzoni; Valentina Fiori; Mario Terracciano; Maria Cristina Manara; Diego Moricoli; Michela Pasello; Marika Sciandra; Giordano Nicoletti; Mara Gellini; Sabrina Dominici; Claudia Chiodoni; Pier Maria Fornasari; Pier-Luigi Lollini; Mario P. Colombo; Piero Picci; Maurizio Cianfriglia; Mauro Magnani; Katia Scotlandi
Biology of Human Tumors
Author Choice
Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma
Pedram Gerami; Robert W. Cook; Jeff Wilkinson; Maria C. Russell; Navneet Dhillon; Rodabe N. Amaria; Rene Gonzalez; Stephen Lyle; Clare E. Johnson; Kristen M. Oelschlager; Gilchrist L. Jackson; Anthony J. Greisinger; Derek Maetzold; Keith A. Delman; David H. Lawson; John F. Stone
Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups
Diana M. Merino; Adam Shlien; Anita Villani; Malgorzata Pienkowska; Stephen Mack; Vijay Ramaswamy; David Shih; Ruth Tatevossian; Ana Novokmet; Sanaa Choufani; Rina Dvir; Myran Ben-Arush; Brent T. Harris; Eugene I. Hwang; Rishi Lulla; Stefan M. Pfister; Maria Isabel Achatz; Nada Jabado; Jonathan L. Finlay; Rosanna Weksberg; Eric Bouffet; Cynthia Hawkins; Michael D. Taylor; Uri Tabori; David W. Ellison; Richard J. Gilbertson; David Malkin
The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling
Chi-Pang Wen; Fanmao Zhang; Dong Liang; Christopher Wen; Jian Gu; Heath Skinner; Wong-Ho Chow; Yuanqing Ye; Xia Pu; Michelle A.T. Hildebrandt; Maosheng Huang; Chien-Hua Chen; Chao Agnes Hsiung; Min Kuang Tsai; Chwen Keng Tsao; Scott M. Lippman; Xifeng Wu
Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression
Te-Sheng Chang; Yu-Chih Wu; Ching-Chi Chi; Wei-Chi Su; Pey-Jium Chang; Kam-Fai Lee; Tao-Hsin Tung; Jui Wang; Jun-Jen Liu; Shui-Yi Tung; Liang-Mou Kuo; Hong-Nerng Ho; Thai-Yen Ling; Yen-Hua Huang
Letters to the Editor
Advertisement